newsfilter
← Latest News
GlobeNewswire·

Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs

PALI
  • Palisade Bio dosed the first patient in the global Phase 2b ASCENTRA-UC trial on October 27, 2026, with top-line results expected in Q4 2027.
  • The FDA cleared the IND application for the Phase 2a ASCENTRA-CD trial on September 22, 2026, with enrollment initiation targeted for Q1 2027.
  • ASCENTRA-UC has activated 29 of 30 U.S. sites and is expanding globally to approximately 115 total sites following regulatory clearances in Canada, Georgia, and ongoing reviews in Europe.
  • The ASCENTRA-UC study will enroll 204 patients with ulcerative colitis to evaluate 15 mg and 30 mg once-daily doses of PALI-2108 against placebo, with a primary endpoint of clinical remission at Week 12.
  • The ASCENTRA-CD program is a single-arm Phase 2a study for Crohn's disease involving 60 adults, with a primary endpoint of endoscopic response at Week 12 and results expected in Q1 2028.
  • New clinical data presented at ACG 2026 included two Presidential Poster Awards, while UEG Week 2026 featured findings on rapid endoscopic improvement in fibrostenotic Crohn's disease.
  • Research and development expenses for the three months ended September 30, 2026, were $10.6 million, representing a significant increase from $1.4 million in the prior year period due to Phase 2 trial start-up activities.
  • General and administrative expenses for the quarter ended September 30, 2026, were $5.1 million, compared to $1.5 million in the same period last year.
  • The Company reported a net loss of $14.6 million, or $0.07 per share, for the quarter ended September 30, 2026.
  • Palisade Bio held $113.6 million in cash and cash equivalents as of September 30, 2026, which is expected to fund operations through key Phase 2 milestones in 2027 and 2028.
Company
Palisade Bio, Inc.
Keywords
Nasdaq:PALI, Palisade Bio, Inc., Palisade Bio, Inc, Nasdaq: PALI, biopharmaceutical company, clinical-stage, oral therapies, immune-mediated, PALI-2108 Phase 2